BioCryst Pharmaceuticals, Inc. (BCRX) was a big mover last session, as the company saw its shares rise over 5% on the day. The share price gain followed the company’s announcement of winning the BCX4430 advanced development contract from the Biomedical Advanced Research and Development Authority (BARDA) in the U.S.
This led to solid volume with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down over 12% in the past one-month time frame.
Although the company did not see any estimate revisions in the past 30 days, its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for BioCryst. So make sure to keep an eye on this stock going forward to see if yesterday’s jump can turn into more strength down the road.
BioCryst Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the computer software industry is MicroStrategy Inc. (MSTR), sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BIOCRYST PHARMA (BCRX): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research